Parenteral Nutrition Market

Parenteral Nutrition Market Outlook from 2024 to 2034

The global parenteral nutrition market recorded sales of USD 5,720.6 million in 2022. The industry experienced a 6.2% year-on-year growth in 2023 and is anticipated to achieve revenue of USD 6,452.0 million in 2024. Over the assessment period from 2024 to 2034, the global sector is projected to expand at a compound annual growth rate (CAGR) of 6.8%, resulting in a size of USD 12,456.8 million by the end of 2034.

A rise in chronic diseases such as cancer, diabetes, and gastrointestinal diseases has resulted in higher demand for specific nutritional support. Such patients usually need parental feeding because they cannot be fed via mouth or enteral route, thus enabling them to maintain their nutrition status.

The increasing number of such patients is propelling the industry’s expansion. The improvements in medical technology and healthcare facilities have made it easier to administer parenteral nutrition. Innovations in formulation, packaging, and delivery systems have improved its efficacy and convenience making it more attractive for use both in hospitals and homecare settings.

Additionally, these technological advancements have also helped reduce complications and risks thereby, improving the confidence levels of healthcare professionals who can now prescribe parenteral nutrition without much concern.

Attributes	Description
Estimated Global Parenteral Nutrition Size (2024E)	USD 6,452.0 million
Projected Global Parenteral Nutrition Value (2034F)	USD 12,456.8 million
Value-based CAGR (2024 to 2034)	6.8 %

Moreover, age bracketing factors have also played a vital role in driving up this business. Older people are prone to malnutrition-related problems due to chronic illnesses, thus necessitating interventions like administration of TPNs. As the elderly population continues growing at alarming rates, so will the demand for these specialized nutritional solutions. Also, increased awareness and education about the benefits of PN as opposed to other alternatives among hospital staff as well as those involved with primary care setup helps significantly towards this trend.

Semi-Annual Market Update

The below table presents a comparative assessment of the variation in CAGR over six months for the base year (2023) and current year (2024) for the global parenteral nutrition market. This analysis reveals crucial shifts in performance and indicates revenue realization patterns, thus providing stakeholders with a better vision of the growth trajectory over the year. The first half of the year, or H1, spans from January to June. The second half, H2, includes the months from July to December.

Particular	Value CAGR
H1	5.5% (2023 to 2033)
H2	5.7% (2023 to 2033)
H1	6.2% (2024 to 2034)
H2	6.8% (2024 to 2034)

In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 5.5 %, followed by a slightly higher growth rate of 5.7 % in the second half (H2) of the same decade. Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to increase slightly to 6.2 % in the first half and remain moderate at 6.8 % in the second half. In the first half (H1) the sector witnessed an increase of 50 BPS while in the second half (H2), the business witnessed a decrease of 20 BPS.

Key Industry Highlights

Enhancement with Technological Advancements in Delivery Systems

Delivery systems for parenteral nutrition are being significantly improved by technological advancements. Some companies are developing sophisticated infusion pumps and catheters, which minimize the risk of infection and complications. For instance, B. Braun has launched smart infusion systems that come with built-in safety measures as well as real-time monitoring features.

Moreover, these can indicate to healthcare providers the onset of troubles such as blockages or air bubbles hence leading to immediate treatments. Furthermore, there is an emphasis on manufacturing user-friendly designs that make ease of administration a reality. Baxter International’s Sigma Spectrum infusion pump for instance has been designed with user-friendly controls thus enabling healthcare givers to deliver accurate nutrition doses easily.

Empowering Patients with Home-Based Methods

The provision of care-at-home is changing patient management by saving resources and time while still improving the quality of life for patients. This has led to the need for long-term nutritional support for chronically ill patients, therefore pushing this trend further ahead. Brands design portable easy-to-use equipment so that patients can independently manage their nutritional needs from anywhere within their homes.

For example, Baxter International’s Home Choice Pro is a portable device used at home by patients who require parenteral nutrition. These gadgets possess safety features that guarantee uninterrupted accuracy on nutrition provision to patients alongside instant notification about anything going wrong.

Additionally, manufacturers provide extensive education and care to assist parents in making good decisions concerning home-based therapy thereby raising confidence levels among guardians. This model not only reduces hospital visits but also cuts medical costs hence offering convenience and ease to the patient.

Integration of Digital Health Technologies

Digital health technologies integration into parenteral nutrition is transforming care delivery and treatment efficiency. Companies are utilizing telemedicine, remote monitoring, and data analysis to provide holistic care for patients. For instance, Nestlé Health Science has developed digital platforms that enable real-time monitoring of patients' nutritional status.

These systems can show healthcare providers a patient’s progress by tracking them from a distance. Moreover, digital health tools enhance the interaction between patients and healthcare providers. This ongoing feedback loop facilitates prompt resolution of any complications as well as optimization of nutritional support. Companies integrating digital health technologies are thereby improving both clinical outcomes and access to care.

2019 to 2023 Global Parenteral Nutrition Sales Analysis Compared to Demand Forecasts for 2024 to 2034

Global sales increased at a CAGR of 6.2 % from 2019 to 2023. For the next ten years (2024 to 2034), projections are that expenditure will rise at 6.8 % CAGR.

The industry grew considerably between 2019 and 2023. This was because of the rise in chronic diseases such as cancer, gastrointestinal disorders, and diabetes that prompted demand for specialized nutritional support. These patients frequently need parenteral nutrition to maintain their nutritional status when they cannot take food through the mouth or intestines.

Medical technological advancement and better healthcare infrastructure made it easier and safer to use such nutrition products. There were improvements in formulation, packaging, and delivery systems, which increased the efficiency and convenience of such nutrition products for both hospital and home care purposes. These changes resulted in lowered risks and complications; hence more confidence by medical practitioners in the prescription of PN.

In the future from 2024 to 2034, the global sector will continue to move ahead, driven by ongoing advancements as well as emerging trends. One aspect that will make this possible is the increasing number of elderly people globally. Considering that elderly people are prone to malnutrition as well as chronic diseases implies that there is demand for products like PN.

Additionally, since companies are using telemedicine, remote monitoring, and data analytics among other technologies to improve patient care quality and treatment efficiency; therefore, individual patient needs can be met through manufacturing specific formulae containing nutrients, most suitable for them, thus ensuring positive outcomes while at the same time cutting down chances of complications.

Market Concentration

Tier 1 refers to the market leaders who have extensive research and development capabilities required to deliver substantial product portfolios and have significant market share. Such companies are responsible for leading innovations in formulation processes, delivery systems, and sustainability aspects. Examples include Baxter International and Fresenius Kabi.

They have a worldwide presence through well-developed distribution channels added with enough resources required for investment in modern technologies. Hence, they enjoy competitive advantages over others because they offer many alternatives depending on the patient’s need. These big sharks hold around 60- 70%of market share.

Tier 2 covers regional players and specialists who either deal with a given segment of the parenteral nutrition sector or concentrate on specific categories. These firms are less popular compared to MNCs, but they are excellent in niche categories or regions.

Examples include B. Braun as well as Grifols. Quite often these organizations have much emphasis on quality aspects and innovations within their respective specializations such as advanced infusion systems, and target patients among others. This is why they quickly adapt to changing business ecosystems or emerging trends, thus maintaining business competitiveness confined to their niches.

Tier 3 features local and emerging enterprises that are newcomers or else operate within a limited scale inside the PN sector. They usually concentrate on serving small regional industries by providing them with cost-effective solutions, which are customized according to the peculiar needs of those.

Although they don’t possess vast resources like larger counterparts do, these companies always give personalized attention and flexibility too. Often, they work together with local healthcare providers in addressing specific nutritional challenges, thereby contributing to the overall variety as well as dynamism that exists within the PN industry.

Country-wise Insights

The following table shows the estimated growth rates of the top three territories. USA and Germany are set to exhibit high consumption, recording CAGRs of 5.4 % and 7.3%, respectively, through 2034.

Countries	CAGR 2024 to 2034
USA	5.4%
Germany	7.3%
China	6.2%
Japan	8.5%
India	9.7%

United States Leading the Global Parenteral Nutrition Industry

The business ecosystem in the United States is projected to exhibit a CAGR of 5.4 % during the assessment period. By 2034, revenue from the sales of this sector in the country is expected to reach USD 3,238.8 million.

One major reason is an increase in obesity levels and related metabolic disorders. Obesity has become a common condition requiring special diets alongside, diabetes or cardiovascular diseases, thus increasing the demand for nutrition solutions tailored to such cases. The robust healthcare infrastructure and advanced medical facilities available in the USA is another important factor.

For this reason, there exist well-equipped hospitals and specialized clinics that make sure patients have access to high-quality products. Moreover, research and development contribute highly towards innovations in formulations as well as delivery systems within the USA.

Demand Outlook in Germany

The demand in Germany is calculated to rise at a CAGR of 7.3 % during the forecast period (2024 to 2034). By 2034, Germany is expected to account for 10.0 % of sales in the world.

Germany is a country that is strongly committed to healthcare quality and patient safety. As such, Germany has strict regulatory standards and a well-developed healthcare system focused on delivering high-quality medical care, meaning that all such product supplies meet stringent safety and efficacy criteria making them readily acceptable for use in clinical settings. Moreover, there is a growing emphasis on preventive medicine coupled with early intervention.

German healthcare providers take proactive measures in identifying and combating cases of nutritional deficiencies among their patients, especially those suffering from chronic diseases or going through major surgeries, thereby increasing demand for better parental nutritional strategies. These strategies are also used as prophylactic measures against hospital-acquired infections, hence reducing the incidence rates amongst affected persons over different periods.

Rapidly Aging Population in Japan is likely to propel sales

Consumption of such nutrition products in Japan is projected to increase at a CAGR of 8.5 % over the next ten years. By 2034, the size is forecasted to reach USD 996.5 million, with Japan expected to account for a share of 8.0 % globally.

One of the main forces behind this is the advanced healthcare technology and infrastructure in the country. Japan is recognized for its state-of-the-art medical innovations and good health standards, which make it easier to use complex nutrition solutions. As a result, there is an increased consumer demand for customers who receive high-quality nutritional care.

Also, Japan’s population is aging at a faster rate, thus significantly impacting the market expansion. This means that there are more elderly people in Japan than anywhere else which results in the need for special nutritional support services when managing age-related health issues. Therefore, this trend raises demand specifically targeted at older individuals.

Category-Wise Insights

Rising Demand for Carbohydrates-Based Nutrition Products

Segment	Carbohydrate (By Nutrient Type)
Value Share (2024)	58.0%

Carbohydrate formulations have evolved in stability and effectiveness, with advancements. The latter encompasses glucose polymers and balanced carbohydrate mixtures as well as a longer longer-lasting energy supply; thus, improved metabolic control decreases complications such as hyperglycemia. These improvements make carbohydrate-based products more appealing to healthcare providers.

Also, the growing prevalence of conditions like sepsis, trauma, and major surgeries that require intensive nutritional support increases the demand for carbohydrate-laden products. Since these diseases are characterized by a need for rapid energy replacement, carbohydrates play a more vital role thereby propelling the growth of the industry.

The adult segment is likely to dominate the sales

Segment	Adults (By Consumer Type)
Value Share (2024)	62.0%

Several key factors drive up sales of adult nutrition products. There is an increase in chronic ailments (e.g., cancer) affecting adults that call for specific dietary requirements. In many cases, nutrient intake or oral absorption gets affected, making such products essential to maintain health status while promoting recovery. Moreover, new kinds of treatments and procedures have led to critically ill patients’ better survival chances, hence requiring them to be on PN in their recovery progressions. The result has been a need for specialized solutions that meet adult patients’ unique requirements.

Competition Outlook

Baxter International, Fresenius Kabi, and B Braun are some of the leading companies that dominate the field supported by their wide range of products and extensive distribution channels globally. These firms concentrate on R&D expenditure to produce innovative product lines that fulfill changing healthcare provider’s needs.

To gain more sales, manufacturers are focusing on strategic partnerships and collaborations. By partnering with hospitals, clinics, and research institutions, they can enhance their market presence and credibility. This also includes clinical trials done with academic institutions aimed at validating new formulations thus promoting product adoption.

For instance

• In 2023, Potassium Phosphates Injection USP was introduced by American Regent which works just like Potassium Phosphates. It is FDA-approved. It supplies phosphorus in IV fluids when low levels are experienced among children and adults who cannot get enough from what they eat or feeding tubes.
• In 2022, Fresenius Kabi announced that their Lipid Injectable Emulsion (ILE) would be available for pediatric patients in the US including both full-term and preterm newborns. It is therefore the first, as well as the only four-oil lipid emulsion that can be used for parenteral nutrition across all ages.

Leading Brands

• B. Braun SE
• Fresenius Kabi USA, LLC.
• Baxter International Inc.
• ICU Medical, Inc.
• Option Care Health Inc.
• Grifols, S.A.
• Otsuka Pharmaceutical Co., Ltd.
• Aculife
• Sichuan Kelun Pharmaceutical Co., ltd.
• Meiji Seika Pharma Co., Ltd.
• Energia Wellbeing Pvt. Ltd.
• Ezen Pharma Inc.
• Claris Lifesciences Ltd.
• JW Pharmaceutical Corporation
• Ferrero Healthcare
• Others

Key Segments of the Report

By Nutrient Type:

As per nutrient type, the industry has been categorized into Single-dose amino acids (Standard and Disease-Specific), carbohydrates, Lipids, and Additives (Vitamins and minerals, Trace Elements, and Organic Phosphates).

By Consumer Type:

This segment is further categorized into Pediatrics, Adults, and Geriatrics.

By Route of Delivery:

As per the route of delivery, the industry has been categorized into Total parenteral nutrition (TPN), and Peripheral parenteral nutrition (PPN).

By Sales Channel:

This segment is further categorized into Institutional Sales (Hospitals, Clinics, Long-Term Care Centres, and Home Care Agencies), and Retail Sales (Retail Pharmacies, Compounding Pharmacies, Online Pharmacies, and Manufacturer Websites).

By Indication:

As per the indication, the industry has been categorized into Neurological Diseases, GI Disorders, Malnutrition, Alzheimer’s, Cancer Care, Chronic Kidney Diseases, Dysphagia, and Others.

By Region:

Industry analysis has been carried out in key countries of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.

Frequently Asked Questions

What is the current value of the parenteral nutrition industry?

The global industry is estimated at a value of USD 6,452.0 million in 2024.

At what rate did the sales for parenteral nutrition grow between 2019 and 2023?

The sales increased at 6.2 % CAGR between 2019 and 2023.

Who are the leading manufacturers of parenteral nutrition?

B. Braun SE, Fresenius Kabi USA, LLC., Baxter International Inc., ICU Medical, Inc., Option Care Health Inc., Grifols, S.A., Otsuka Pharmaceutical Co., Ltd., Aculife, Sichuan Kelun Pharmaceutical Co., ltd., and Meiji Seika Pharma Co., Ltd. are some of the leading players in this business.

Which region will garner a significant value share by 2024?

The North American territory is projected to hold a revenue share of 34.1 % over the forecast period.

At what CAGR is the global parenteral nutrition industry forecasted to grow from 2024 to 2034?

The industry is projected to grow at a forecast CAGR of 6.8 % from 2024 to 2034.